ISO/IEC 42001 in pharma: what the AI management system standard actually requires.

ISO/IEC 42001 was published 18 December 2023 as the first international management-system standard specifically for AI. The architecture follows the Annex SL high-level structure that ISO 9001, ISO 13485, ISO 14001, and ISO 27001 all share: context, leadership, planning, support, operation, performance evaluation, improvement. A pharma quality function reading it for the first time recognises every clause heading. The novelty is not the architecture; it is the AI-specific elaboration in clauses 6, 8, and the controls in Annex A and Annex B.

/ 01Where 42001 overlaps existing pharma QMS.

The overlap is substantial. Risk management framing in clause 6 maps cleanly onto ICH Q9(R1). Operational planning and control in clause 8 maps onto ICH Q10 process performance and product quality monitoring. Documented information in clause 7.5 maps onto the document control discipline already in ISO 13485 / 21 CFR 820. Internal audit, management review, nonconformity, corrective action — these are clauses that any ISO 9001 / 13485 certified pharma is already operating. Re-implementing them under 42001 branding is rework without value.

The cheap implementation is to read 42001 as a delta against the existing QMS. Identify what 42001 adds; do not re-document what 42001 shares. The expensive implementation is to build a parallel 42001 management system alongside the pharma QMS — produces two sets of records, two audit cycles, two governance committees, twice the cost without twice the value.

/ 02Where 42001 fills genuine gaps.

AI impact assessment at clause 6.1.4.

The AI system impact assessment — covering individuals, groups, and society — is the artefact most missing from the existing pharma QMS. ICH Q9(R1) does product risk; 42001 adds AI-specific impact assessment that includes fairness, transparency, autonomy, contestability. For a pharma QMS that has historically read risk through patient-safety and product-quality lenses only, the impact-assessment clause adds a frame the QMS does not natively carry.

AI system life cycle at clause 8.

42001 clause 8.3 references AI system life cycle stages — inception, design and development, verification and validation, deployment, operation, monitoring, decommissioning — with controls in Annex A specifically for each. The pharma QMS handles product life cycle and equipment life cycle; the AI system life cycle is a third register. It is the same life-cycle architecture the EU AI Act, FDA AI/ML SaMD guidance, and GMP Annex 22 all use. 42001 is the management-system anchor for that life cycle.

Data for AI specifically.

Clause 8.4 elaborates on data acquisition, preparation, quality, and provenance specifically for AI training, validation, and operation. The pharma QMS handles GMP data, GLP data, GCP data — each within their regulatory regimes. AI training data is a data class the pharma QMS has not historically had to govern. 42001 names the controls; the implementation work is to attach them to the existing data-management infrastructure.

The standard is generic because it has to span every industry. The pharma reading is what makes it operational. Without the pharma reading, 42001 is checklist Esperanto. With it, the standard becomes the AI extension to the QMS already in place.

/ 03Where 42001 is too generic for pharma.

The standard's controls are written for any AI deployer in any industry. The specific failure modes that matter in regulated life sciences — hallucination in pharmacovigilance, drift in bioanalytical method support, non-deterministic output in regulatory submission generation — are not addressed at the resolution they need. 42001 anchors the management system; it does not substitute for the regulator-specific operational guidance. The companies that read 42001 as sufficient will be inadequate to FDA AI/ML SaMD, EU AI Act, GMP Annex 22, and the regulator-specific reflection papers.

The companies that read 42001 as the management-system frame — and read FDA, EMA, EU AI Act, GMP Annex 22 as the operational layer feeding into it — will have a coherent governance posture. The arrangement is hierarchical: 42001 is the QMS-level standard; FDA AI/ML SaMD is the use-case-level guidance; ICH M10 v2 is the bioanalytical-specific guidance; GMP Annex 22 is the manufacturing-specific guidance. They stack rather than substitute.

/ 04The certification question.

42001 certification is available from the major bodies — BSI, DNV, TÜV, Lloyd's, Bureau Veritas — and a small but growing number of pharma sponsors are pursuing it through 2026. The business case is partially regulatory-anticipatory (the EU AI Act conformity assessment regime will reward demonstrable management-system maturity) and partially market-positioning (procurement RFPs from larger pharma asking smaller AI-vendor partners about 42001 status are appearing in 2026).

For a pharma sponsor whose AI footprint is internal — not vending AI products to other pharma — the immediate value of certification is lower. The internal benefit of operating as if 42001-certified, without paying for the certificate, is high. The clean position for most mid-cap pharma in 2026 is to align without certifying. Larger pharma should weigh whether the procurement-side signalling justifies the certification cost.

/ 05The integration sequence.

Pragmatic 42001 alignment for a pharma already running ISO 13485 or ICH Q10:

• Read each 42001 clause; identify whether the existing QMS already satisfies it
• For clauses partially covered, document the gap as a delta; address in the next QMS revision cycle
• For clauses not covered (impact assessment, AI life cycle, AI data governance), draft the new SOPs and integrate into the existing QMS document hierarchy
• Update the QMS scope statement to include AI systems explicitly
• Run an internal audit against 42001 alongside the next regular ISO audit cycle
• Resolve gaps; decide whether external certification adds enough value to pursue

The architecture is in the governance library; this note is the standard-specific reading. 42001 is the international anchor that lets the regulated-life-sciences AI conversation reference a single management-system standard rather than thirty divergent national approaches. That is the value, even before the regulator-specific layers stack on top.